BioNexus Gene Lab Corp BGLC
BioNexus Gene Lab Corp. is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd. ("Chemrex") and MRNA Scientific Sdn. Bhd. ("MRNA Scientific"). Chemrex is engaged in the distribution of chemical raw materials, primarily for industrial applications in Southeast Asia. MRNA Scientific is engaged in the development and provision of blood-based genomic screening services intended to support early disease risk assessment and health management.
In November 2025, the Company entered into a Share Subscription and Shareholders' Agreement with Fidelion Diagnostics Pte. Ltd. ("Fidelion") and related parties, and also entered into an exclusive Southeast Asia intellectual property license arrangement relating to the VitaGuard™ minimal residual disease platform. These transactions expanded the Company's strategic focus in molecular diagnostics and oncology-related screening technologies.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.4M | $9.5M | $9.8M | $10.9M | $13.4M | $11.4M | $127.0K | $212.3K | — |
| Cost of revenue | $6.3M | $8.2M | $8.4M | $9.7M | $11.1M | $9.7M | $71.1K | -$183.6K | — |
| Gross profit | $1.1M | $1.3M | $1.3M | $1.3M | $2.3M | $1.7M | $55.9K | $28.8K | — |
| R&D | $50.7K | $47.5K | $55.0K | — | — | — | — | — | — |
| SG&A | $1.5M | $1.8M | $2.4M | $1.7M | $1.3M | $1.3M | $356.6K | -$241.9K | — |
| Total operating expenses | $4.5M | $4.9M | -$4.4M | — | — | — | — | — | — |
| Operating income | -$3.0M | -$1.6M | -$2.6M | -$291.2K | $1.1M | $1.3M | -$275.7K | $59.9K | — |
| Interest expense | — | — | $13.9K | $12.5K | — | — | — | — | — |
| Pre-tax income | -$3.0M | -$1.6M | -$2.6M | -$303.7K | $1.0M | — | -$221.7K | $59.9K | — |
| Income tax | $0 | $3.5K | $21.5K | $52.3K | $291.3K | — | $24.8K | $33.4K | — |
| Net income | -$3.0M | -$1.6M | -$2.6M | -$356.0K | $751.6K | $1.1M | -$246.5K | $26.5K | — |
| EPS, diluted | — | -0.09 | -0.17 | — | — | 0.01 | 0.00 | 0.00 | — |
| Shares, diluted (wtd. avg.) | — | 17.8M | 15.9M | — | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $2.5M | $2.9M | $4.5M | $2.1M | $2.1M | $2.8M | $859.1K | $1.3M | — |
| Receivables | $505.9K | $1.4M | — | — | — | — | — | — | — |
| Inventory | $676.7K | $1.4M | $1.1M | $977.8K | $1.5M | $1.2M | $7.6K | $15.3K | — |
| Total current assets | $5.4M | $7.4M | $8.0M | $6.0M | $7.1M | $8.0M | $882.6K | $1.3M | — |
| Property, plant and equipment | $1.6M | $1.5M | $1.5M | $1.5M | $1.6M | $1.8M | $312.9K | $341.8K | — |
| Total assets | $9.3M | $10.4M | $11.4M | $8.7M | $9.6M | $10.1M | $1.2M | $1.7M | — |
| Accounts payable | — | $1.5M | $1.4M | $1.9M | $2.0M | — | — | — | — |
| Total current liabilities | $521.0K | $2.0M | $1.6M | $2.0M | $2.3M | $3.4M | $51.6K | $62.9K | — |
| Total liabilities | $637.9K | $2.1M | $1.7M | $2.1M | $2.4M | $3.5M | $108.9K | $130.3K | — |
| Retained earnings | -$6.4M | -$3.4M | -$1.8M | $1.2M | $1.5M | $760.8K | -$333.3K | -$86.8K | — |
| Total equity | $8.6M | $8.3M | $9.7M | $6.7M | $7.2M | $6.7M | $1.1M | $1.5M | $94.6K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.8M | -$2.1M | -$1.8M | $551.8K | $9.2K | $552.7K | -$217.3K | -$274.1K | — |
| Depreciation and amortisation | $111.9K | $104.2K | $83.3K | $91.4K | $91.3K | $90.8K | $41.7K | $40.6K | — |
| Stock-based compensation | $794.8K | $141.0K | — | — | — | — | — | — | — |
| Capital expenditure | $37.0K | $227.0K | $149.4K | $0 | $3.2K | $421.6K | $12.8K | $39.6K | — |
| Investing cash flow | $944.8K | $418.2K | -$1.8M | -$450.5K | -$490.6K | $1.3M | -$12.8K | -$51.7K | — |
| Financing cash flow | $298.8K | $4.0K | $6.3M | $108.2K | -$28.2K | -$4.9K | -$180.8K | $742.9K | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001477932-26-002218.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $212.3K | $127.0K | $11.4M | $13.4M | $10.9M | $9.8M | $9.5M | $7.4M |
| Gross profit | — | $28.8K | $55.9K | $1.7M | $2.3M | $1.3M | $1.3M | $1.3M | $1.1M |
| Net income | — | $26.5K | -$246.5K | $1.1M | $751.6K | -$356.0K | -$2.6M | -$1.6M | -$3.0M |
Recent filings and events
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Other event Item 8.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event Item 8.01
- Other event Item 8.01
- Other event Item 8.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Other event Item 8.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Regulation FD disclosure Item 7.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 8071
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| NTRA | Natera, Inc. | $58.23B | — | 35.9% |
| DGX | QUEST DIAGNOSTICS INC | $26.70B | 27.6x | 11.8% |
| LH | LABCORP HOLDINGS INC. | $26.68B | 31.4x | 7.2% |
| GH | Guardant Health, Inc. | $22.69B | — | 32.9% |
| CAI | Caris Life Sciences, Inc. | $9.04B | — | 97.0% |
| GRAL | GRAIL, Inc. | $5.92B | — | 17.2% |
| RDNT | RadNet, Inc. | $5.54B | — | 11.5% |
| BLLN | BillionToOne, Inc. | $5.00B | 769.8x | 100.0% |